Global Erythropoietin (EPO) Drugs Market Research Report 2023-2031: Biosimilars and Patent Expirations Drive Transformation in the EPO Landscape - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Erythropoietin Drugs Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.

The global erythropoietin drugs market was valued at USD 10.3 billion in 2022, driven by the increasing prevalence of chronic kidney disease and the increasing incidence of cancer across the globe. The market size is anticipated to grow at a CAGR of 5.7% during the forecast period of 2023-2031 to achieve a value of USD 17 billion by 2031.

The Erythropoietin (EPO) drugs market is a vital segment of the pharmaceutical industry that focuses on the development and distribution of medications aimed at stimulating red blood cell production. EPO drugs play a crucial role in managing anaemia, particularly in patients with chronic kidney disease, cancer, or undergoing certain medical procedures like chemotherapy or dialysis.

The market for EPO drugs is driven by several factors, including the rising prevalence of chronic kidney disease and the increasing incidence of cancer globally. The aging population, diabetes, and hypertension are contributing to the growing prevalence of chronic kidney disease, leading to a higher demand for EPO drugs. Additionally, the use of EPO drugs in oncology has expanded significantly as they help manage anaemia associated with cancer and its treatments.

Advancements in drug delivery systems have also been a key driver in the market. The development of long-acting EPO formulations and sustained-release implants has improved patient convenience and compliance by reducing the frequency of drug administration.

In summary, the EPO drugs market is driven by factors such as the rising prevalence of chronic kidney disease and the increasing use of EPO drugs in oncology. Advancements in drug delivery systems, the entry of biosimilars, and regulatory compliance are key trends shaping the market. As the demand for effective anaemia management continues to rise, the market for EPO drugs is expected to grow further, driven by innovation and adherence to regulatory requirements.

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.

Key Trends in the Erythropoietin Drugs Market

Rising Prevalence of Chronic Kidney Disease (CKD): The increasing prevalence of CKD, driven by factors such as aging population, diabetes, and hypertension, is a major driver for the growth of the EPO drugs market. CKD often leads to anemia, and EPO drugs are an important treatment option to manage anemia in these patients

Growing Use in Oncology: EPO drugs are widely used in the field of oncology to manage anemia associated with chemotherapy and cancer-related conditions. As the incidence of cancer continues to rise globally, the demand for EPO drugs in cancer care is expected to increase

Advancements in Drug Delivery Systems: The development of new drug delivery systems, such as long-acting EPO formulations and sustained-release implants, is a key trend in the EPO drugs market. These advancements aim to enhance patient convenience and adherence by reducing the frequency of drug administration

Biosimilars and Patent Expirations: The market for EPO drugs has witnessed the entry of biosimilars, which are highly similar versions of the original EPO drugs. The availability of biosimilars has increased competition and led to cost savings for healthcare systems. Additionally, the expiration of patents for some originator EPO drugs has further contributed to market growth

The major companies in the market are as follows:

• Amgen Inc
• Biocon Limited
• Dr. Reddy's Laboratories Ltd
• F. Hoffmann-La Roche AG
• Intas Pharmaceuticals Ltd
• Johnson & Johnson
• LG Chem Ltd
• Pfizer Inc
• Sun Pharmaceutical Industries Limited
• Teva Pharmaceutical Industries Ltd

Patent Analysis

• Analysis by Type of Patent
• Analysis by Publication year
• Analysis by Issuing Authority
• Analysis by Patent Age
• Analysis by CPC Analysis
• Analysis by Patent Valuation
• Analysis by Key Players

Grants Analysis

• Analysis by year
• Analysis by Amount Awarded
• Analysis by Issuing Authority
• Analysis by Grant Application
• Analysis by Funding Institute
• Analysis by NIH Departments
• Analysis by Recipient Organization

Clinical Trials Analysis

• Analysis by Trial Registration Year
• Analysis by Trial Status
• Analysis by Trial Phase
• Analysis by Therapeutic Area
• Analysis by Geography

Funding and Investment Analysis

• Analysis by Funding Instances
• Analysis by Type of Funding
• Analysis by Funding Amount
• Analysis by Leading Players
• Analysis by Leading Investors
• Analysis by Geography

Partnership and Collaborations Analysis

• Analysis by Partnership Instances
• Analysis by Type of Partnership
• Analysis by Leading Players
• Analysis by Geography

Erythropoietin Drugs Market Segmentations

Market Breakup by Drug Type

• Biologics
• Biosimilars

Market Breakup by Product Type

• Epoetin-alfa
• Epoetin-beta
• Darbepoetin-alfa
• Others

Market Breakup by Application

• Haematology
• Kidney Disorder
• Cancer
• Others

Market Breakup by End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

For more information about this report visit https://www.researchandmarkets.com/r/b7m8sk

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900